Mizunari Yosuke, Nagaoka Masato, Takeshita Naohiro, Kanno Kazuki, Hirayama Haruyuki, Akutsu Taisuke, Kessoku Hisashi, Ishida Katsuhiro, Yamamoto Yutaka
Department of Otolaryngology, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
Department of Otolaryngology, The Jikei University School of Medicine, Tokyo, Japan.
Front Oncol. 2025 Aug 15;15:1530922. doi: 10.3389/fonc.2025.1530922. eCollection 2025.
Carcinoma of the external auditory canal (EAC) is rare, and squamous cell carcinoma (SCC) is the most common histological type. There are few reports on the treatment outcomes for a large number of cases at a single institution, and a standard treatment has not been established.
Treatment details and prognoses were retrospectively examined for patients who underwent primary treatment for SCC of the EAC at The Jikei University between April 2015 and May 2023.
Twenty-seven patients with SCC of the EAC were included (median age of 64 years). Analysis using the revised Pittsburgh classification revealed that there were 3 cases of T1, 4 cases of T2, 9 cases of T3, and 11 cases of T4. Among the patients, 13 were treated surgically, 1 underwent partial resection of the EAC, 11 underwent lateral temporal bone resection, and 1 underwent subtotal temporal bone resection. The remaining 14 patients received nonsurgical treatment: 1 with radiotherapy, 3 with concurrent chemoradiotherapy, and 10 with induction chemotherapy (ICT). The overall survival (OS) and disease-free survival (DFS) rates at 3 years were 72.8% and 50.5%, respectively. When the surgical and non-surgical groups were compared, the 3-year OS and DFS rates were 92.3% and 68.3% for those who underwent surgery and 47.6% and 35.7% for those not treated with surgery, respectively, suggesting a better prognoses for patients who underwent surgical treatments ( = 0.045, 0.052). In the non-surgical group, the 3-year OS and DFS rates were 90.0% and 50.0% for those who received ICT and 0% and 0% for those who did not receive ICT, respectively, indicating better prognoses for patients treated with ICT ( = 0.0075, 0.0012).
At our institution, the 3-year OS and DFS rates of patients with SCC of the EAC were favourable for those who underwent surgery and received ICT. These findings suggest that treatment outcomes can be improved by using ICT in nonsurgical treatments for patients with SCC of the EAC.
外耳道癌（EAC）较为罕见，鳞状细胞癌（SCC）是最常见的组织学类型。关于单一机构大量病例的治疗结果报道较少，且尚未确立标准治疗方案。
回顾性研究2015年4月至2023年5月在东京慈惠会医科大学接受EAC的SCC初次治疗患者的治疗细节和预后情况。
纳入27例EAC的SCC患者（中位年龄64岁）。采用修订的匹兹堡分类法分析显示，T1期3例，T2期4例，T3期9例，T4期11例。其中，13例接受手术治疗，1例行EAC部分切除术，11例行颞骨外侧切除术，1例行颞骨次全切除术。其余14例患者接受非手术治疗：1例接受放射治疗，3例接受同步放化疗，10例接受诱导化疗（ICT）。3年总生存率（OS）和无病生存率（DFS）分别为72.8%和50.5%。比较手术组和非手术组，手术患者的3年OS和DFS率分别为92.3%和68.3%，未手术患者分别为47.6%和35.7%，提示手术治疗患者预后较好（P = 0.045，0.052）。在非手术组中，接受ICT患者的3年OS和DFS率分别为90.0%和50.0%，未接受ICT患者均为0%，表明接受ICT治疗患者预后较好（P = 0.0075，0.0012）。
在本机构，EAC的SCC患者接受手术和ICT治疗的3年OS和DFS率较好。这些结果表明，在EAC的SCC患者非手术治疗中使用ICT可改善治疗效果。
